Our Technology
Non-invasive measurements of gases
The innovative technology behind Neola® is based on GASMAS (Gas in Scattering Media Absorption Spectroscopy) method – an innovative non-invasive laser spectroscopy method for measuring gases in body cavities that has been patented by Neola Medical. GASMAS was originally developed by researchers at Division of Atomic Physics at Lund University and originally proven in industrial applications such as food, pharmaceutical, and beverage quality control.
The technology has been further refined by Neola Medical, holding all rights and patents for the medical application of GASMAS. This patented technology aims to bring a new dimension of safety and precision to neonatal intensive care, while potentially reducing the need for harmful X-ray imaging and invasive blood sampling.
GASMAS – Gas In Scattering Media Absorption Spectroscopy
GASMAS uses tunable diode laser spectroscopy and leverages the unique light absorption characteristics of oxygen and water vapor molecules, properties that differ from those of liquids and solid tissues.
Applying GASMAS in Neola®
Neola® uses small, lightweight probes with soft adhesive, designed for the delicate skin of preterm born babies. One probe emits low-intensity near-infrared light through the chest cavity, while another detects the light after it has passed through tissue. The near-infrared light is harmless, causes no significant heating, and is safe for the baby.
A small portion of the light passes through the air-filled cavities of the lungs, where it is absorbed by water vapor and oxygen gas molecules. Advanced algorithms then process this signal to register changes in lung volume and oxygen gas concentration.
NEOLA®
Neonatal Lung Analyzer
Neola® is a stand-alone device placed next to the incubator (a unit that helps infants maintain body temperature and facilitates observation) to monitor the baby. It consists of a main unit with a modern touch screen and accompanying disposable probes that are attached to the baby’s body to perform the measurements. The touch screen continuously displays the values for relative lung volume and oxygen gas concentration in the right and left lung, which are also stored for later analysis.
Monitoring both lungs
Two probes are placed on opposite sides of the chest to continuously monitor each lung independently.
Non-invasive and safe
The probes are entirely non-invasive and do not cause harmful heating of the baby’s delicate skin.
Easily placed and repositioned
The probes can easily be removed and repositioned during routine care, minimizing discomfort and unnecessary stress for the baby.
Single use probe sets
The probes are non-sterile, changed daily and intended for one single patient use only.
Professor Katarina Svanberg and Professor Sune Svanberg
The technology founders
The GASMAS technology behind Neola® was pioneered by Professor Sune Svanberg, a distinguished physicist and former member of the Nobel Prize selection committee for Physics, together with his wife, Professor Katarina Svanberg, an award-winning renowned medical doctor and highly respected chief physician.
The first lung measurements using the GASMAS technology were published in 2011 by Märta Lewander Xu, now Chair of the Board at Neola Medical. This work was conducted during her doctoral studies under the supervision of Professor Sune Svanberg and co-supervision by Professor Katarina Svanberg.
Keynote lecture on GASMAS technology
Neola Medical is proud to have had the opportunity to participate and showcase its GASMAS technology in the Xth RECENT ADVANCES IN NEONATAL MEDICINE Congress, held from October 12-14, 2024, in Würzburg, Germany. This prestigious event brought together over 500 of the world’s leading neonatal care experts, providing an invaluable platform for knowledge exchange and progress in the MedTech field.
At the Congress, Neola Medical was honored to sponsor a highly anticipated keynote lecture by esteemed U.S. Professor Vineet Bhandari, Division Head of Neonatology at The Children’s Regional Hospital at Cooper, Camden, USA. His presentation, titled “GASMAS Transit to the NICU – Are We There Yet?”, provided valuable insights into the potential of GASMAS technology to enhance clinical outcomes for preterm born babies.
CEO Hanna Sjöström and MD DM Professor Vineet Bhandari, Division Head of Neonatology at The Children’s Regional Hospital at Cooper, Camden, USA.
“The potential of GASMAS technology in modern neonatal care is an exciting step forward in neonatal medicine, and I look forward to sharing its potential future with healthcare professionals from around the world.”
– Professor Vineet Bhandari
GASMAS Transit to the NICU – Are We There Yet?
Expert insights from Professor Bhandari
This exclusive three-part video series captures Professor Vineet Bhandari’s keynote lecture from the Xth RECENT ADVANCES IN NEONATAL MEDICINE Congress.
Each segment offers valuable insights into how GASMAS technology could enhance neonatal care and improve clinical outcomes for preterm born babies.
Part 1
Part 2
Part 3
Neonatal Lung Monitoring
The innovative technology behind Neola® has the potential to advance how neonatal intensive care units monitor lung function, moving from intermittent and invasive checks to safe, continuous, real-time monitoring.
Impact beyond the NICU
While Neola® is developed for preterm born babies, the technology could be adapted for older children and adults in intensive care settings, addressing an unmet need in respiratory monitoring across all ages.
Platform for future innovation
With strong patent protection and clinically validated potential, Neola Medical’s technology positions the company as a leader in advanced, non-invasive respiratory monitoring for neonatal intensive care.
Invest in Neola Medical
At Neola Medical, our mission is to provide preterm born babies with a stronger and safer start in life. Through our innovative medical device, Neola®, we aim to advance neonatal intensive care by offering non-invasive, continuous, real-time lung monitoring, with the potential to support proactive care, reduce morbidity and improve quality of life for these vulnerable patients.
"We aim to detect lung complications immediately, giving healthcare professionals the tools they need to make life-saving decisions."
– Hanna Sjöström, CEO Neola Medical